US Stock MarketDetailed Quotes
FULC Fulcrum Therapeutics
- 3.880
- +0.030+0.78%
Close Dec 2 16:00 ET
209.28MMarket Cap-13379P/E (TTM)
3.980High3.780Low500.72KVolume3.820Open3.850Pre Close1.95MTurnover1.53%Turnover RatioLossP/E (Static)53.94MShares13.70052wk High0.81P/B127.27MFloat Cap2.86052wk Low--Dividend TTM32.80MShs Float33.098Historical High--Div YieldTTM5.20%Amplitude2.250Historical Low3.885Avg Price1Lot Size
About Fulcrum Therapeutics Company
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
Company Profile
SymbolFULC
Company NameFulcrum Therapeutics
Listing DateJul 18, 2019
Issue Price16.00
Founded2015
CEOMr. Alex C. Sapir
MarketNASDAQ
Employees76
Fiscal Year Ends12-31
Address26 Landsdowne Street
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02139
Phone1-617-651-8851
Websitehttp://www.fulcrumtx.com
Company Executives
- Name
- Position
- Salary
- Alex C. Sapir
- Director, President and Chief Executive Officer
- 6.99M
- Alan A. Musso
- Chief Financial Officer and Treasurer
- 1.88M
- Dr. Patrick Taylor Horn, M.D.,PhD.
- Chief Medical Officer
- --
- Curtis G. Oltmans
- Chief Legal Officer
- 2.32M
- Gregory Tourangeau
- Vice President, Finance, Controller and Principal Accounting Officer
- --
- Melvin H. Hayes, III
- Executive Vice President, Patient Experience
- 2.19M
- Kate Haviland
- Chairman of the Board
- 157.90K
- Dr. Robert J. Gould, PhD
- Director
- 424.50K
- Rachel King
- Independent Director
- --
- Sonja Banks
- Independent Director
- 121.40K
- Katina Dorton, J.D.,M.B.A.
- Independent Director
- 136.40K
- Colin Hill
- Independent Director
- --
- James A. Geraghty
- Independent Director
- 131.90K
- Dr. Alan Ezekowitz, D.Phil.,MB.Ch.B.
- Independent Director
- 131.40K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data